Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study

Bone Marrow Transplantation volume 27, pages 1221–1225 (2001)Cite this article

Abstract

Relapse after allogeneic progenitor cell transplant is associated with a poor prognosis for patients with advanced leukemia, with few curative options available. Use of novel chemotherapeutic agents with limited toxicity is warranted. We investigated the role of decitabine, a pyrimidine analogue with significant anti-leukemic effect and limited toxicity, in this setting. Fourteen patients with advanced acute leukemia or transformed chronic myelogenous leukemia (CML) who had failed previous allogeneic transplant were treated. Decitabine at doses of 100 mg/m2 to 150 mg/m2 given every 12 h for 5 days was followed by infusion of stem cells from the original donor 2 to 5 days after the completion of chemotherapy. Dose of decitabine was escalated in cohorts of three patients based on the modified Fibonacci scheme. The primary study end-point was assessment of the toxicity of the regimen with secondary endpoints of response and survival. Eight patients responded with either a complete remission or partial hematological remission (absence of blasts in peripheral blood and bone marrow but with platelet count <100 × 109/l). Toxicity was limited with no grade 3 or 4 toxicity directly attributable to the treatment. The median survival for all patients was 190 days (range 11 to 1215+ days). Decitabine at doses of 100 mg/m2 to 150 mg/m2 given every 12 h for 5 days, followed by stem cell infusion from the original donor was well tolerated, and was associated with acceptable myelosuppression. Current response data should encourage further study of this drug, either alone or in combination with other agents, for treatment of relapsed acute leukemia after an allogeneic transplant. Bone Marrow Transplantation (2001) 27, 1221–1225.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Frassoni F, Barrett AJ, Granena A et al. Relapse after allogeneic bone marrow transplantation for acute leukemia: a survey by the EBMTR of 117 cases Br J Haematol 1988 70: 317–320

    Article  CAS  PubMed  Google Scholar 

  2. Mortimer J, Blinder M, Schulman S et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy J Clin Oncol 1989 7: 50–57

    Article  CAS  PubMed  Google Scholar 

  3. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation Blood 1995 86: 4337–4343

    CAS  PubMed  Google Scholar 

  4. Issa J-PJ, Baylin SB, Herman JG . DNA methylation changes in hematologic malignancies: biologic and clinical implications Leukemia 1997 11: (Suppl. 1) S7–S11

    PubMed  Google Scholar 

  5. Pliml J, Sorm F . Synthesis of 2′-deoxy-D-ribofuranosyl-5-azacytosine Coll Czech Chem Commun 1964 29: 2576–2577

    Article  CAS  Google Scholar 

  6. Sorm F, Vesely J . Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice Neoplasma 1968 15: 339–343

    CAS  PubMed  Google Scholar 

  7. Pinto A, Zagonei V . 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemia and myelodysplastic syndromes: past, present and future trends Leukemia 1993 7: 51–60

    PubMed  Google Scholar 

  8. Santi DV, Garrett CE, Barr PJ . On the mechanism of inhibition of DNA-cytosine methyltransferase by cytidine analogs Cell 1983 83: 9–10

    Article  Google Scholar 

  9. Momparler RL, Bouchard J, Samson J . Induction of differentiation and inhibition of DNA methylation in HL60 myeloid leukemic cells by 5-aza-2′-deoxycytidine Leukemia Res 1985 9: 1361–1366

    Article  CAS  Google Scholar 

  10. Pinto A, Attadia V, Fusco A et al. 5-aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemia Blood 1984 64: 922–929

    CAS  PubMed  Google Scholar 

  11. Pinto A, Maio M, Attadia V et al. Modulation of HLA-DR antigen expression in human myeloid leukemic cells by cytarabine and 5-aza-2′-deoxycytidine Lancet 1984 2: 867–868

    Article  CAS  PubMed  Google Scholar 

  12. Pinto A, Zagonel V, Attadia V et al. 5-aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukemias and myelodysplastic syndromes of the elderly Bone Marrow Transplant 1989 4: (Suppl. 2) 28–32

    PubMed  Google Scholar 

  13. Giralt S, Davis M, O'Brien S et al. Studies of decitabine with allogeneic progenitor cell transplantation Leukemia 1997 11: (Suppl. 1) S32–S34

    PubMed  Google Scholar 

  14. Rivard GE, Momparler RL, Demers J et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia Leukemia Res 1981 5: 452–462

    Article  Google Scholar 

  15. Momparler RL, Gyger M, Rivard GE . Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia Pharmacol Ther 1985 30: 277–286

    Article  CAS  PubMed  Google Scholar 

  16. Richel DJ, Colly LP, Kluin-Nelemans JC et al. The antileukemic activity of 5-aza-2′-deoxycytidine (Aza-dC) in patients with relapsed and resistant acute leukemia Br J Cancer 1991 64: 144–148

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Bearman S, Appelbaum F, Buckner C et al. Regimen related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562–1568

    Article  CAS  PubMed  Google Scholar 

  18. Gluksberg H, Storb R, Fefer A et al. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors Transplantation 1974 18: 295–304

    Article  Google Scholar 

  19. Schulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host disease syndrome in man . A long term clinical pathologic study of 20 Seattle patients Am J Med 1980 69: 204–217

    Article  Google Scholar 

  20. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party on Chronic Leukemia Blood 1995 86: 2041–2050

    CAS  PubMed  Google Scholar 

  21. Sanders JE, Buckner CD, Clift RA et al. Second marrow transplants for patients with leukemia who relapse after allogeneic marrow transplantation Bone Marrow Transplant 1988 3: 11–21

    CAS  PubMed  Google Scholar 

  22. Giles FJ, Cortes JF, Beran M et al. Phase I study of BCH4556 in patients with advanced leukemia Proc ASCO 1999 18: 28a (Abstr.)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    F Ravandi, H Kantarjian, A Cohen, M Davis, S O'Brien, P Anderlini, B Andersson, D Claxton, M Donato, J Gajewski, I Khouri, M Korbling, N Ueno, R Champlin & S Giralt

  2. Pharmachemie BV, Haarlem, The Netherlands

    D deVos

Authors
  1. F Ravandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S O'Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Anderlini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Claxton
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Donato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Gajewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. I Khouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Korbling
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. N Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. D deVos
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. R Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ravandi, F., Kantarjian, H., Cohen, A. et al. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 27, 1221–1225 (2001). https://doi.org/10.1038/sj.bmt.1703028

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703028

Keywords

This article is cited by

Search

Advanced search

Quick links